Results 1 to 4 of 4
Page 1 of 1
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant diseaseYuen, MF; Han, KH; Um, SH; Yoon, SK; Kim, HR; Kim, J; Kim, CR; Lai, CL201097
Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBVLai, CL; Han, KH; Yoon, SK; Um, SH; Yuen, MF; Kim, HS; Kim, HR; Chung, HC; Kim, CR; Hsyu, P; Averett, D; Worland, S; Kim, J2006207
A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis BYuen, MF; Kim, J; Kim, CR; Ngai, V; Yuen, JCH; Min, C; Kang, HM; Shin, BS; Yoo, SD; Lai, CL2006179
Phase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection.Yuen, RMF; Kim, J; Averett, D; Wong, DKH; Kim, CR; Kerr, B; Ngai, WS; Yuen, JCH; Lai, CL2004189
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download